The role of STAT3 activation in modulating the immune microenvironment of GBM

Journal of Neuro-Oncology

Volumn 110, Issue 3, 2012, Pages 359-368

  See, Alfred P ^a   Han, James E ^b   Phallen, Jillian ^b   Binder, Zev ^a,c   Gallia, Gary ^a   Pan, Fan ^d   Jinasena, Dilini ^d   Jackson, Christopher ^a   Belcaid, Zineb ^b   Jeong, Sung Jin ^b   Gottschalk, Chelsea ^b   Zeng, Jing ^a   Ruzevick, Jacob ^a   Nicholas, Sarah ^b   Kim, Young ^a   Albesiano, Emilia ^d   Pardoll, Drew M ^d   Lim, Michael ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

^c Johns Hopkins University   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Glioblastoma multiforme (GBM); Immunotherapy; Signal transducer and activator of transcription 3 (STAT3); Small molecule inhibitor

Indexed keywords

CHEMOKINE; CYTOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; RANTES; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL ACTIVATION; CELL MATURATION; DENDRITIC CELL; GEL MOBILITY SHIFT ASSAY; GLIOBLASTOMA; HUMAN CELL; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOTHERAPY; IN VITRO STUDY; MICROENVIRONMENT; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

AMINOSALICYLIC ACIDS; BENZENESULFONATES; BLOTTING, WESTERN; BRAIN NEOPLASMS; CHEMOKINES; CYTOKINES; DENDRITIC CELLS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GLIOBLASTOMA; HUMANS; LIPOPOLYSACCHARIDES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TUMOR CELLS, CULTURED;

EID: 84871336215     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-012-0981-6     Document Type: Article

References (43)

1. Prasad G, Wang H, Hill DL, Zhang R (2004) Recent advances in experimental molecular therapeutics for malignant gliomas. Curr Med Chem Anticancer Agents 4:347-361
2. Zagzag D, Salnikow K, Chiriboga L, Yee H, Lan L, Ali MA, Garcia R, Demaria S, Newcomb EW (2005) Downregulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brain. Lab Invest 85:328-341
3. Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, Cachola KE, Murray JC, Tihan T, Jensen MC, Mischel PS, Stokoe D, Pieper RO (2007) Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 13:84-88
4. Akasaki Y, Liu G, Chung NHC, Ehtesham M, Black KL, Yu JS (2004) Induction of a CD4(+) T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma. J Immunol 173:4352-4359
5. Rahaman SO, Harbor PC, Chernova O, Barnett GH, Vogelbaum MA, Haque SJ (2002) Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene 21:8404-8413
6. Kortylewski M, Jove R, Yu H (2005) Targeting STAT3 affects melanoma on multiple fronts. Cancer Metastasis Rev 24:315-327
7. Ma X-T, Wang S, Ye Y-J, Du R-Y, Cui Z-R, Somsouk M (2004) Constitutive activation of Stat3 signaling pathway in human colorectal carcinoma. World J Gastroenterol 10:1569-1573
8. Yu H, Pardoll D, Jove R (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9:798-809
9. Wang TH, Niu GL, Kortylewski M, Burdelya L, Shain K, Zhang SM, Bhattacharya R, Gabrilovich D, Heller R, Coppola D, Dalton W, Jove R, Pardoll D, Yu H (2004) Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 10:48-54
10. Wang J, Wang X, Hussain S, Zheng Y, Sanjabi S, Ouaaz F, Beg A (2007) Distinct roles of different NF-kappa B subunits in regulating inflammatory and T cell stimulatory gene expression in dendritic cells. J Immunol 178:6777-6788
11. Yu H, Kortylewski M, Pardoll D (2007) Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7:41-51
12. Burdelya L, Kujawski M, Niu GL, Zhong B, Wang TH, Zhang SM, Kortylewski A, Shain K, Kay H, Djeu J, Dalton W, Pardoll D, Wei S, Yu H (2005) Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects. J Immunol 174:3925-3931
13. Hoentjen F, Sartor RB, Ozaki M, Jobin C (2005) STAT3 regulates NF-kappa B recruitment to the IL-12p40 promoter in dendritic cells. Blood 105:689-696
14. Herbeuval JP, Lelievre E, Lambert C, Dy M, Genin C (2004) Recruitment of STAT3 for production of IL-10 by colon carcinoma cells induced by macrophage-derived IL-6. J Immunol 172:4630-4636
15. Zhong Z, Wen ZL, Darnell JE (1994) STAT3 - a STAT family member activated by tyrosine phosphorylation in response to epidermal growth-factor and interleukin-6. Science 264:95-98
16. Ogura H, Murakami M, Okuyama Y, Tsuruoka M, Kitabayashi C, Kanamoto M, Nishihara M, Iwakura Y, Hirano T (2008) Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction. Immunity 29:628-636
17. Takeda K, Clausen BE, Kaisho T, Tsujimura T, Terada N, Forster I, Akira S (1999) Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 10:39-49
18. Kinjyo I, Inoue H, Hamano S, Fukuyama S, Yoshimura T, Koga K, Takaki H, Himeno K, Takaesu G, Kobayashi T, Yoshimura A (2006) Loss of SOCS3 in T helper cells resulted in reduced immune responses and hyperproduction of interleukin 10 and transforming growth factor-beta 1. J Exp Med 203:1021-1031
19. Matsumura Y, Kobayashi T, Ichiyama K, Yoshida R, Hashimoto M, Takimoto T, Tanaka K, Chinen T, Shichita T, Wyss-Coray T, Sato K, Yoshimura A (2007) Selective expansion of Foxp3-positive regulatory T cells and immunosuppression by suppressors of cytokine signaling 3-deficient dendritic cells. J Immunol 179:2170-2179
20. Zou WP (2006) Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6:295-307
21. Mizoguchi M, Betensky RA, Batchelor TT, Bernay DC, Louis DN, Nutt CL (2006) Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival. J Neuropathol Exp Neurol 65:1181-1188
22. Hussain SF, Kong L-Y, Jordan J, Conrad C, Madden T, Fokt I, Priebe W, Heimberger AB (2007) A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res 67:9630-9636
23. Fujita M, Zhu X, Sasaki K, Ueda R, Low KL, Pollack IF, Okada H (2008) Inhibition of STAT3 promotes the efficacy of adoptive transfer therapy using type-1 CTLs by modulation of the immunological microenvironment in a murine intracranial glioma. J Immunol 180:2089-2098
24. Kostianovsky AM, Maier LM, Anderson RC, Bruce JN, Anderson DE (2008) Astrocytic regulation of human monocytic/microglial activation. J Immunol 181:5425-5432
25. Siddiquee K, Zhang S, Guida WC, Blaskovich MA, Greedy B, Lawrence HR, Yip MLR, Jove R, McLaughlin MM, Lawrence NJ, Sebti SM, Turkson J (2007) Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci USA 104:7391-7396
26. Schust J, Sperl B, Hollis A, Mayer TU, Berg T (2006) Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol 13:1235-1242
27. Yu CL, Meyer DJ, Campbell GS, Larner AC, Cartersu C, Schwartz J, Jove R (1995) Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 269:81-83
28. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(T)(-Delta Delta C) method. Methods 25:402-408
29. Liu J, Xu X, Feng X, Zhang B, Wang J (2011) Adenovirus-mediated delivery of bFGF small interfering RNA reduces STAT3 phosphorylation and induces the depolarization of mitochondria and apoptosis in glioma cells U251. J Exp Clin Cancer Res 30:80
30. Albesiano E, Davis M, See AP, Han JE, Lim M, Pardoll DM, Kim Y (2010) Immunologic consequences of signal transducers and activators of transcription 3 activation in human squamous cell carcinoma. Cancer Res 70:6467-6476
31. Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, Giovannone AJ, Lin JW, Chute DJ, Mischel PS, Cloughesy TF, Roth MD (2005) Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 11:5515-5525
32. Yamanaka R, Homma J, Yajima N, Tsuchiya N, Sano M, Kobayashi T, Yoshida S, Abe T, Narita M, Takahashi M, Tanaka R (2005) Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res 11:4160-4167
33. De Vleeschouwer S, Fieuws S, Rutkowski S, Van Calenbergh F, Van Loon J, Goffin J, Sciot R, Wilms G, Demaerel P, Warmuth-Metz M, Soerensen N, Wolff JEA, Wagner S, Kaempgen E, Van Gool SW (2008) Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res 14:3098-3104
34. Wheeler CJ, Black KL, Liu G, Mazer M, Mazer M, Zhang X-X, Pepkowitz S, Goldfinger D, Ng H, Irvin D, Yu JS (2008) Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res 68:5955-5964
35. Yu JS, Liu GT, Ying H, Yong WH, Black KL, Wheeler CJ (2004) Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 64:4973-4979
36. Karman J, Ling CY, Sandor M, Fabry Z (2004) Initiation of immune responses in brain is promoted by local dendritic cells. J Immunol 173:2353-2361
37. Jacobs JFM, Idema AJ, Bol KF, Grotenhuis JA, de Vries IJM, Wesseling P, Adema GJ (2010) Prognostic significance and mechanism of Treg infiltration in human brain tumors. J Neuroimmunol 225:195-199
38. Jacobs JFM, Idema AJ, Bol KF, Nierkens S, Grauer OM, Wesseling P, Grotenhuis JA, Hoogerbrugge PM, de Vries IJM, Adema GJ (2009) Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. Neuro Oncol 11:394-402
39. Garcia R, Yu CL, Hudnall A, Catlett R, Nelson KL, Smithgall T, Fujita DJ, Ethier SP, Jove R (1997) Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ 8:1267-1276
40. Sato T, Neilson LM, Peck AR, Liu C, Tran TH, Witkiewicz A, Hyslop T, Nevalainen MT, Sauter G, Rui H (2011) Signal transducer and activator of transcription-3 and breast cancer prognosis. Am J Cancer Res 1:347-355
41. Fernandes A, Hamburger AW, Gerwin BI (1999) Erbb-2 kinase is required for constitutive STAT 3 activation in malignant human lung epithelial cells. Int J Cancer 83:564-570
42. Grandis J, Drenning S, Chakraborty A, Zhou M, Zeng Q, Pitt A, Tweardy D (1998) Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth in vitro. J Clin Invest 102:1385-1392
43. Watson CJ, Miller WR (1995) Elevated levels of members of the stat family of transcription factors in breast-carcinoma nuclear extracts. Br J Cancer 71:840-844